Tlr9 - toll-like receptor 9 Gene

Species: Rattus norvegicus

Gene Type: protein coding
Gene ID: 338457

About Tlr9

Primary_assembly 8: 106,864,680-106,868,796 forward strand.mRatBN7.2:CM026981.1

This gene has 1 transcript (splice variant), 81 orthologues, 24 paralogues and is associated with 72 phenotypes. Biased expression in Spleen (RPKM 43.7), Thymus (RPKM 8.) and 5 other tissues.

Summary

Enables unmethylated CpG binding activity. Involved in several processes, including cellular response to lipopolysaccharide; male gonad development; and microglial cell activation. Located in plasma membrane. Biomarker of acute necrotizing pancreatitis; mastitis; and perinatal necrotizing enterocolitis. Human ortholog(s) of this gene implicated in several diseases, including allergic bronchopulmonary aspergillosis; cystic fibrosis; glomerulonephritis (multiple); hepatitis B; and lung disease (multiple). Orthologous to human TLR9 (toll like receptor 9). [provided by Alliance of Genome Resources, Apr 2022]

Tlr9 Products (1)

mRNA Protein Name
NM_198131.1 NP_937764.1 toll-like receptor 9 precursor

Gene Ontology

  • Molecular Function
  • Biological Process
Molecular Function GO Annotation Evidence Verweise Source
enables unmethylated CpG binding IDA
IDA: Inferred from direct assay
16973131 RGD
Biological Process GO Annotation Evidence Verweise Source
involved in cellular response to lipopolysaccharide IEP
IEP: Inferred from expression pattern
20655116 RGD
involved in cellular response to metal ion IEP
IEP: Inferred from expression pattern
17415764 RGD
involved in defense response to virus IMP
IMP: Inferred from mutant phenotype
17202329 RGD
involved in male gonad development IEP
IEP: Inferred from expression pattern
19703144 RGD
involved in microglial cell activation IDA
IDA: Inferred from direct assay
16973131 RGD
involved in positive regulation of autophagy IDA
IDA: Inferred from direct assay
18632594 RGD
involved in toll-like receptor signaling pathway IDA
IDA: Inferred from direct assay
16973131 RGD
EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern

Tlr9 Protein Structure

LRR_RI

LRR_RI: sd00033 (42 - 63)

PLN00113

PLN00113: cl33413 (62 - 593)

LRR_RI

LRR_RI: sd00033 (64 - 87)

LRR_RI

LRR_RI: sd00033 (88 - 123)

LRR_RI

LRR_RI: sd00033 (124 - 143)

LRR_RI

LRR_RI: sd00033 (144 - 167)

LRR_RI

LRR_RI: sd00033 (168 - 199)

LRR_RI

LRR_RI: sd00033 (200 - 220)

LRR_RI

LRR_RI: sd00033 (221 - 244)

LRR_RI

LRR_RI: sd00033 (245 - 284)

LRR_RI

LRR_RI: sd00033 (285 - 308)

LRR_RI

LRR_RI: sd00033 (309 - 334)

LRR_RI

LRR_RI: sd00033 (335 - 364)

LRR_RI

LRR_RI: sd00033 (392 - 415)

LRR_RI

LRR_RI: sd00033 (476 - 497)

LRR

LRR: COG4886 (478 - 763)

LRR_RI

LRR_RI: sd00033 (498 - 522)

LRR_RI

LRR_RI: sd00033 (523 - 546)

LRR_RI

LRR_RI: sd00033 (547 - 576)

LRR_RI

LRR_RI: sd00033 (577 - 629)

LRR_RI

LRR_RI: sd00033 (600 - 617)

LRR_RI

LRR_RI: sd00033 (630 - 654)

LRR_RI

LRR_RI: sd00033 (655 - 678)

LRR_RI

LRR_RI: sd00033 (679 - 702)

LRR_RI

LRR_RI: sd00033 (703 - 726)

LRR_RI

LRR_RI: sd00033 (727 - 745)

LRR_RI

LRR_RI: sd00033 (752 - 773)

TIR_2

TIR_2: cl23749 (869 - 1012)

  • 0
  • 200
  • 400
  • 600
  • 800
  • 1032 a.a.
Protein Preferred Names Protein Names

toll-like receptor 9

Related Agents

  • Approval
  • Clinical Phase
  • Pre-clinical Phase

Approval

Bioactive Molecules (3)
Art. -Nr. Produktname Wirkung
Reinheit Rare Diseases
HY-B1370 Hydroxychloroquine sulfate Inhibitor 99.99% Yes
HY-B1370B (R)-Hydroxychloroquine Inhibitor / Unkown
HY-B1370A (S)-Hydroxychloroquine Inhibitor / Unkown

Clinical Phase

Bioactive Molecules (6)
Art. -Nr. Produktname Wirkung
Reinheit Phase
HY-150218 Agatolimod sodium Agonist 99.13% Phase 3
HY-148511 Vidutolimod Agonist 93.85% Phase 3
HY-150724C ODN 1018 sodium Agonist 97.49% Phase 2
HY-177617A Bazlitoran sodium Agonist 95.30% Phase 2
HY-177617 Bazlitoran Agonist 95.30% Phase 2
HY-178166 ETI41 Inhibitor / Phase 1

Pre-clinical Phase

Bioactive Molecules (35)
Art. -Nr. Produktname
Wirkung
Reinheit
Rare Diseases
HY-146245 ODN 1826 Agonist 99.69% Unkown
HY-146245C ODN 1826 sodium Agonist 99.51% Unkown
HY-146244 Agatolimod Agonist 98.84% Unkown
HY-150741C ODN 2216 sodium Agonist 98.57% Unkown
HY-150741 ODN 2216 Agonist 98.57% Unkown
HY-N0201 Atractylenolide I Antagonist 99.98% Unkown
HY-150724 ODN 1018 Agonist 99.28% Unkown
HY-150743 ODN 2395 Agonist 98.39% Unkown
HY-150726C ODN 1668 sodium Agonist 98.79% Unkown
HY-124603 AT791 Inhibitor 98.77% Unkown
HY-150743C ODN 2395 sodium Agonist 98.20% Unkown
HY-148045 TLR9-IN-1 Inhibitor 99.67% Unkown
HY-12756 E6446 Antagonist 98.78% Unkown
HY-150726 ODN 1668 Agonist 99.03% Unkown
HY-12756A E6446 dihydrochloride Antagonist 99.29% Unkown
HY-150750 ODN M362 Agonist 96.01% Unkown
HY-150217A CpG ODN 10101 sodium Agonist 98.84% Unkown
HY-150217 CpG ODN 10101 Agonist 99.44% Unkown
HY-B1370R Hydroxychloroquine sulfate (Standard) Inhibitor 99.96% Unkown
HY-101929 CU-CPT17e Agonist 98.67% Unkown
HY-150736 ODN 20844 Inhibitor 96.14% Unkown
HY-146245F FAM-labeled ODN 1826 sodium Agonist 98.03% Unkown
HY-114592 M199 Inhibitor 98.55% Unkown
HY-150744 ODN 24888 Inhibitor / Unkown
HY-150745 ODN 24987 Inhibitor / Unkown
HY-150212 Tilsotolimod Inhibitor 99.46% Unkown
HY-178037 TLR9 antagonist 1 Antagonist / Unkown
HY-179474 TSI-13-57 Inhibitor 98.73% Unkown
HY-150219A ODN M326 sodium Inhibitor / Unkown
HY-180507 TLR2/9 antagonist 1 Antagonist / Unkown
HY-179209 TLR9-IN-2 Inhibitor / Unkown
HY-178169 ETI60 Inhibitor 99.51% Unkown
HY-150219 ODN M326 Agonist / Unkown
HY-183079 ENDO12 Inhibitor / Unkown
HY-183400 BIM-46174 Inhibitor / Unkown

Orthologs Information

Species Symbol Source ID
Homo sapiens Tlr9 NCBI NCBI:54106